Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

We conducted this study to determine the feasibility and safety of cladribine followed by rituximab in patients with hairy cell leukemia including the vari-ant form (HCLv). Cladribine 5.6 mg/m(2) given IV over 2 hours daily for 5 days was followed ∼ 1 month later with rituximab 375 mg/m(2) IV weekly...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Ravandi, Farhad, O'Brien, Susan, Jorgensen, Jeffrey, Pierce, Sherry, Faderl, Stefan, Ferrajoli, Alessandra, Koller, Charles, Challagundla, Pramoda, York, Sergernne, Brandt, Mark, Luthra, Rajyalakshmi, Burger, Jan, Thomas, Deborah, Keating, Michael, Kantarjian, Hagop
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2011
Pynciau:
Clinical Trials and Observations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4081440/
https://ncbi.nlm.nih.gov/pubmed/21821712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-04-351502
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg